Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-29

Clinical Trial Update: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

View source ↗

Summary

A clinical trial evaluating Abrocitinib in adults with moderate to severe atopic dermatitis has been terminated, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abrocitinib (abrocitinib)

Snippet

Sponsor: Pfizer | Conditions: Dermatitis, Atopic | Status: TERMINATED | Results posted: 2025-09-29